This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Reed, E. Search for Related Content PubMed PubMed Citation Articles by Reed, E.

ERCC1 and Clinical Resistance to Platinum-Based Therapy

Author's Affiliation: Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, The Centers for Disease Control and Prevention, Atlanta, Georgia

Requests for reprints: Eddie Reed, Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, The Centers for Disease Control and Prevention, 4770 Buford Highway, Mailstop: K-52, Atlanta, GA 30341. Phone: 770-488-4237; Fax: 770-488-4760; E-mail: duf7{at}cdc.gov.

Praz and colleagues report in this issue on the relationship between the occurrence of a polymorphism of ERCC1 in tumor tissues of patients with colorectal cancer and the rate of disease response to the combination of oxaliplatin and 5-fluorouracil (1). This polymorphism is associated with reduced translation of the gene, and presumably, reduced DNA repair capability. Their report suggests that the ability of cells/tissues to up-regulate ERCC1 seems to be correlated with whether or not the patient will respond to oxaliplatin-based therapy. This ERCC1 polymorphism, and its implications, was first reported by others (2, 3). It is important to understand the molecular pharmacology of oxaliplatin, as well as the basic issues about ERCC1.

Oxaliplatin is the third platinum analogue to be approved by the Food and Drug Administration for clinical use. Cisplatin, carboplatin, and oxaliplatin have a number of molecular differences, but are similar in critical ways (4). The most important similarities revolve around the cis configuration of the two reactive groups of the platinum core of the molecule. This cis bond angle is relatively fixed and results in covalent bonding with DNA and other molecules, where the target molecule conforms to fit the bond angle of the platinum moiety. In the case of platinum-DNA adduct, this fixed bond angle for platinum results in bifunctional DNA lesions that contort the DNA to accommodate the platinum. Thus, DNA kinking is a major feature of platinum-DNA damage, which is recognized and repaired by the nucleotide excision repair pathway. Structurally, similar lesions are formed with DNA after interactions with UV light and with polycyclic aromatic hydrocarbons, all of which are recognized and repaired by nucleotide excision repair.

There are four basic DNA repair pathways: nucleotide excision repair, base excision repair, mismatch repair, and double-strand break repair (5–7). Each pathway has its own set of proteins that function entirely independently of the other pathways. Experimental data suggest that there is also cross-functionality of these pathways, but for the most part, these four pathways are separate. Nucleotide excision repair processes bulky lesions such as UV dimers, 6-4 UV photoproducts, polycyclic aromatic hydrocarbons, and cisplatin-DNA lesions. Base excision repair processes oxidative DNA damage and simple alkylation damage to DNA bases. Mismatch repair processes DNA strand slippage, mismatches in DNA base alignments, and ensures fidelity of replication during cellular division. Double-strand break repair is critically important for protecting against particularly potent DNA damaging agents, such as X-ray irradiation.

ERCC1 is an excision nuclease within the nucleotide excision repair pathway (5–7). ERCC1 forms a heterodimer with XPF. As a unit, they execute the 5' incision into the DNA strand, relative to the site of DNA damage, in the nucleotide excision repair excision process. Studies by Sancar and Reardon (6) show that the 5' excision is the last of several steps that are specific to excision of a platinum-DNA lesion. ERCC1 is one of the 16 proteins that compose the nucleotide excision repair repairosome.

ERCC1 is highly conserved through nature, with analogues in E. coli and in plants (5, 7–9). The gene is located on chromosome 19 and has 10 exons spread over 15 kb of genome. Multiple splice variants of the full-length gene product have been described or hypothesized to exist. A functional ERCC1 is essential to life. Mice with an ERCC1 knockout die shortly after weaning, and there is one case in the literature of a human baby that died shortly after birth who may have had a nonfunctional ERCC1. In mouse models, normal ERCC1 function is critical to normal aging, normal brain development, and normal immunoglobulin switching. The only cell line that exists without a functional ERCC1 is very difficult to maintain in culture. Therefore, we have comparatively little direct knowledge about ERCC1 functionality. This gene may be important in several biological pathways that are not yet fully described.

Based on studies done in the laboratory, we understand some of the issues that relate to the ERCC1 influence on repair of platinum-DNA damage. In Chinese hamster ovary cells that have a defective ERCC1, transfection of ERCC1 into those cells restores the ability to repair cisplatin-DNA adduct (10). Human ovarian cancer cells that express ERCC1 mRNA to higher levels also show higher levels of resistance to platinum drug exposures (11). Where ERCC1 is up-regulated, so are the other genes in the nucleotide excision repair repairosome (12). The presence of alternatively spliced ERCC1 mRNA is inversely related to DNA repair efficiency in a range of cell lines (13–15). Up-regulation of ERCC1, XPA, and other nucleotide excision repair genes occurs in the absence of mutations or gene amplifications of these genes (16, 17). Transfection of a dominant negative to activator protein 1 into human ovarian cancer cells down-regulates ERCC1 and sensitizes cells to cisplatin (18). In addition, drugs that down-regulate ERCC1 also inhibit cisplatin-DNA adduct repair and make the treated cells more sensitive to platinum drugs (reviewed in ref. 3). ERCC1 has several splice variants and one known polymorphism that seems to influence the activity of the full-length gene product (2, 3, 13–15). This polymorphism seems to reduce the rate at which translation of the gene into protein can occur.

The regulatory control of ERCC1 expression is also of substantial interest. ERCC1 seems to be up-regulated by activator protein 1, which in this case is a heterodimer of jun and fos (19). This up-regulation can be effected through the jun kinase system or the extracellular signal-regulated kinase system. The bigger picture, however, is more interesting. ERCC1 is one of the 16 proteins in the nucleotide excision repair repairosome. A computer-based analysis was done to assess the possibility that all 16 of these proteins might be regulated by the same transcription factors (20). The analysis strongly suggests this possibility. Further, in each case where it has been studied, the genes in the nucleotide excision repair repairosome (ERCC1, XPA, XPB, XPD, etc.) are highly expressed together or expressed in low levels together (refs. 11, 21–25, and other reports). Activator protein 1 is clearly an important positive transcriptional regulator, and there are several candidates for clinically important negative transcriptional regulators. A more detailed study of the in vitro effects of specific transcription factors on each of the nucleotide excision repair repairosome proteins has yet to be done.

One practical aspect of these 16 nucleotide excision repair genes being acted on by the same regulatory proteins has to do with overall DNA repair function. Known DNA repair defects are the result of one specific protein being mutated or not present. Conversely, it is clear that for the DNA repair system to work best, all proteins in this process should be up-regulated together, down-regulated together, etc. This has been studied in human brain tissues as well as in cell lines. In brain tissues (24, 25), normal tissues have tightly coordinated mRNA expressions of all studied genes within the nucleotide excision repair repairosome. This suggests excellent DNA repair efficiency. High-grade malignant brain tissues have a much reduced level of coordination of mRNA expression patterns for the same genes. This suggests much lowered DNA repair efficiency. Low-grade malignant brain tissues have a pattern that is intermediate between the two. This has been interpreted to offer one reason why malignant brain tissues will show greater sensitivity to DNA damaging agents than the adjacent normal brain tissues when they are concurrently exposed. Thus, one has a differential in tissue sensitivity to DNA damaging therapies related to DNA repair efficiency.

One study attempted to assess whether or not there was an order to the up-regulation of these genes, or if these genes were independently regulated. The study assessed the static representation of several nucleotide excision repair genes from the repairosome in human ovarian cancer tissues (26). The study suggested that ERCC1 up-regulation must occur first in the nucleotide excision repair cascade (26). However, even if the suggested order of genes is not mandatory, the polymorphism reported (1–3) would result in limited available ERCC1 protein, which would limit the activity of the nucleotide excision repair process.

Malignancies in which mRNA expression of ERCC1 is directly related to clinical outcome in response to DNA damaging chemotherapy include lung cancer, head and neck cancers, gastric cancer, colorectal cancer, and ovarian cancer (data reviewed in ref. 3). Tissue culture studies suggest that other diseases where this relationship might be important include testicular cancer, bladder cancer, cervical cancer, and others (data reviewed in ref. 3). This leaves open the question on why ERCC1 protein does not show similar correlations. It is the view of this author that ERCC1 protein that is active is complexed with the 15 other proteins in the nucleotide excision repair repairosome, and is not readily accessible to antibody binding. This would explain the difficulty in assessing the active portion of total ERCC1 protein (i.e., that which is truly participating in the DNA repair process). Meanwhile, mRNA levels of ERCC1 have repeatedly shown to be useful in giving clinically relevant information about the nucleotide excision repair pathway.

The current study (1) indicates that molecular assessment of the tumor tissues may give meaningful clinical information with respect to planning platinum-based therapies. This study also provides evidence to suggest the possibility that we may learn to pharmacologically exploit our emerging knowledge of nucleotide excision repair (and possibly other DNA repair pathways) for clinical benefit.

	Footnotes

 
Commentary on Viguier et al., p. 6212

Received 5/16/05; accepted 5/25/05.

	References

Top References

 

1. Viguier J, Boige V, Miguel C, et at., ERCC1 Codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5- fluorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin Can Res 2005;11:6212–17.[Abstract/Free Full Text]
2. Yu JJ, Mu C, Lee KB, et al. A nucleotide polymorphism in ERCC1 gene in human ovarian cancer cell lines and tumor tissues. Mutat Res 1997;382:13–20.[Medline]
3. Yu JJ, Lee KB, Mu C, et al. Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene. Int J Oncol 2000;16:555–60.[Medline]
4. Reed E. Cisplatin, Carboplatin, and Oxaliplatin. In: Chabner BA, Longo DL, editors. Cancer chemotherapy and biotherapy: principles and practice. 4th ed. Philadelphia; Lippincott, Williams & Wilkins. In press 2005.
5. Altaha R, Liang X, Yu JJ, Reed E. ERCC-1 gene expression and platinum resistance. Int J Mol Med 2004;14:959–70.[Medline]
6. Sancar A, Reardon JT. Nucleotide excision repair in E. coli and man. Adv Protein Chem 2004;69:43–71.[Medline]
7. Reed E. Platinum-DNA adduct, nucleotide excision repair, and platinum based anti-cancer chemotherapy. Cancer Treat Rev 1998;24:331–44.[CrossRef][Medline]
8. Mitchell JR, Hoeijmakers JH, Niedernhofer LJ. Divide and conquer: nucleotide excision repair battles cancer and aging. Curr Opin Cell Biol 2003;15:232–40.[CrossRef][Medline]
9. van Duin M, deWit J, Odijk H, et al. Molecular characterization of the human excision repair gene ERCC1: cDNA cloning and amino acid homology with the yeast DNA repair gene RAD10. Cell 1986;44:913–23.[CrossRef][Medline]
10. Lee KB, Parker RJ, Bohr VA, Cornelison TC, Reed E. Cisplatin sensitivity/resistance in UV-repair deficient Chinese hamster ovary cells of complementation groups 1 and 3. Carcinogenesis 1993;14:2177–80.[Abstract/Free Full Text]
11. Li Q, Yu JJ, Mu C, Slavsky D, et al. Association between the level of ERCC1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells. Anticancer Res 2000;20:645–52.[Medline]
12. Dabholkar M, Thornton K, Vionnet J, Bostick-Bruton F, Yu JJ, Reed E. Increased mRNA levels of XPB and CSB without increased mRNA levels of MDR1 or MT-II in platinum-resistant human ovarian cancer tissues. Biochem Pharmacol 2000;60:1611–9.[CrossRef][Medline]
13. Yu JJ, Mu C, Dabholkar M, Bostick-Bruton F, Reed E. Alternative splicing of ERCC1 and cisplatin-DNA adduct repair in human tumor cell lines. Int J Mol Med 1998;1:617–20.[Medline]
14. Yu JJ, Thornton K, Guo Y, Kotz H, Reed E. An ERCC1 splicing variant involving the 5'UTR of the mRNA may have a transcriptional modulatory function. Oncogene 2001;20:7694–8.[CrossRef][Medline]
15. Dabholkar M, Vionnet J, Parker RJ, Bostick-Bruton F, Dobbins A, Reed E. Expression of an alternatively spliced ERCC1 mRNA species, is related to reduced DNA repair efficiency in human T lymphocytes. Oncology Rep 1995;2:209–14.
16. States JC, Reed E. Enhanced XPA mRNA levels in cisplatin-resistant human ovarian cancer are not associated with XPA mutations or gene amplification. Cancer Lett 1996;108:233–7.[CrossRef][Medline]
17. Yu JJ, Bicher A, Bostick-Bruton F, Reed E. Absence of evidence for allelic loss or allelic gain for ERCC1 and for XPD in human ovarian cancer cells and tissues. Cancer Lett 2000;151:127–32.[CrossRef][Medline]
18. Bonovich M, Olive M, Reed E, O'Connell B, Vinson C. Adenoviral delivery of A-FOS, an AP-1 dominant negative, selectively inhibits drug resistance in two human cancer cell lines. Cancer Gene Ther 2002;9:62–70.[CrossRef][Medline]
19. Li Q, Gardner K, Zhang L, Tsang B, Bostick-Bruton F, Reed E. Cisplatin induction of ERCC1 mRNA expression in A2780/CP70 human ovarian cancer cells. J Biol Chem 1998;273:23419–25.[Abstract/Free Full Text]
20. Zhong Z, Thornton K, Reed E. Computer based analyses of the 5'-flanking regions of selected genes involved in the nucleotide excision repair excision complex. Int J Oncol 2000;17:375–80.[Medline]
21. Dabholkar M, Bostick-Bruton F, Weber C, Egwuagu C, Bohr VA, Reed E. Expression of excision repair genes in non-malignant bone marrow from cancer patients. Mutat Res 1993;293:151–60.[Medline]
22. Dabholkar M, Vionnet JA, Bostick-Bruton F, Yu JJ, Reed E. mRNA Levels of XPAC and ERCC1 in ovarian tumor tissue correlates with response to platinum containing chemotherapy. J Clin Invest 1994;94:703–8.
23. Dabholkar M, Bostick-Bruton F, Weber C, Bohr VA, Egwuagu C, Reed E. ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J Natl Cancer Inst 1992;84:1512–7.[Abstract/Free Full Text]
24. Dabholkar MD, Berger MS, Vionnet JA, et al. Malignant and non-malignant brain tissues differ in their mRNA expression patterns for ERCC1 and ERCC2. Cancer Res 1995;55:1261–6.[Abstract/Free Full Text]
25. Dabholkar MD, Berger MS, Vionnet JA, et al. Comparative analyses of relative ERCC3 and ERCC6 mRNA levels in gliomas and adjacent non-neoplastic brain. Mol Carcinog 1996;17:1–7.[CrossRef][Medline]
26. Reed E, Dabholkar M, Thornton K, Thompson C, Yu JJ, Bostick-Bruton F. Evidence for order in the appearance of mRNAs of nucleotide excision repair genes, in human ovarian cancer tissues. Oncol Rep 2000;7:1123–8.[Medline]

This article has been cited by other articles:

				R. Gao, D. K. Price, T. Sissung, E. Reed, and W. D. Figg Ethnic disparities in Americans of European descent versus Americans of African descent related to polymorphic ERCC1, ERCC2, XRCC1, and PARP1 Mol. Cancer Ther., May 1, 2008; 7(5): 1246 - 1250. [Abstract] [Full Text] [PDF]

				E. V. Stevens, S. Nishizuka, S. Antony, M. Reimers, S. Varma, L. Young, P. J. Munson, J. N. Weinstein, E. C. Kohn, and Y. Pommier Predicting cisplatin and trabectedin drug sensitivity in ovarian and colon cancers Mol. Cancer Ther., January 1, 2008; 7(1): 10 - 18. [Abstract] [Full Text] [PDF]

				Y. Pommier DNA Repair Modulators as Anticancer Agents ASCO Educational Book, January 1, 2008; 2008(1): 128 - 133. [Abstract] [Full Text] [PDF]

				G. Simon, A. Sharma, X. Li, T. Hazelton, F. Walsh, C. Williams, A. Chiappori, E. Haura, T. Tanvetyanon, S. Antonia, et al. Feasibility and Efficacy of Molecular Analysis-Directed Individualized Therapy in Advanced Non-Small-Cell Lung Cancer J. Clin. Oncol., July 1, 2007; 25(19): 2741 - 2746. [Abstract] [Full Text] [PDF]

				K. M. Darcy, C. Tian, and E. Reed A Gynecologic Oncology Group Study of Platinum-DNA Adducts and Excision Repair Cross-Complementation Group 1 Expression in Optimal, Stage III Epithelial Ovarian Cancer Treated with Platinum-Taxane Chemotherapy Cancer Res., May 1, 2007; 67(9): 4474 - 4481. [Abstract] [Full Text] [PDF]

				E. Reed ERCC1 measurements in clinical oncology. N. Engl. J. Med., September 7, 2006; 355(10): 1054 - 1055. [Full Text] [PDF]

				M. Wrensch, J. K. Wiencke, J. Wiemels, R. Miike, J. Patoka, M. Moghadassi, A. McMillan, K. T. Kelsey, K. Aldape, K. R. Lamborn, et al. Serum IgE, Tumor Epidermal Growth Factor Receptor Expression, and Inherited Polymorphisms Associated with Glioma Survival. Cancer Res., April 15, 2006; 66(8): 4531 - 4541. [Abstract] [Full Text] [PDF]

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Reed, E. Search for Related Content PubMed PubMed Citation Articles by Reed, E.